Sickle Cell Disease Trial, Recruiting NCT06725550 Sponsor: Indiana University Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Sickle Cell Disease Trial, Recruiting

NCT06725550
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People of any gender between the ages of 14 and 17 (teenagers) or 18 and 80 years old
  • People who are right-handed
  • People who are being treated as outpatients, inpatients, or moving between both types of care
  • People who have been diagnosed with sickle cell disease (any type, such as SS, SC, or others) and have had ongoing pain in the past 6 months, or a painful crisis episode in the past 12 months
  • People who have been prescribed pain or sickle cell medications by their doctor (such as morphine, oxycodone, hydroxyurea, or others) — having these medications is allowed but not required
  • People who are willing to avoid starting new pain treatments or medications during the study visits
  • People who are able to travel to the study site for appointments (which include questionnaires, brain scans, and other tests) and receive acupuncture sessions up to twice a week for 5 weeks
  • People who are fluent in English and able to sign a written consent form

Who may not be able to join:

  • People who currently have, or are suspected of having, COVID-19
  • People who have had acupuncture or similar treatments for pain in the past 6 months
  • People with known blood clotting problems or very low platelet counts that could make acupuncture unsafe (those with mildly low platelets may still be considered — confirm with trial site)
  • People who have another condition that causes ongoing pain — such as rheumatoid arthritis, lupus, or inflammatory bowel disease — where that pain is worse than their sickle cell pain
  • People with a history of a serious head injury with significant loss of consciousness
  • People with nerve damage (from a cause other than sickle cell disease) that interferes with daily activities
  • People with a serious mental health condition not related to sickle cell disease, such as schizophrenia or severe depression with thoughts of suicide
  • People with significant vision, movement, or hearing problems that would prevent them from completing study activities
  • People who have started or changed the dose of stimulant medications (such as Adderall or Ritalin) within the past 30 days
  • People who cannot have an MRI scan due to metal implants, surgical clips, certain dental materials, heart rhythm problems, seizure disorders, or other MRI-related safety concerns
  • People who have had vascular surgery on their lower legs, or who have current circulation problems in their lower legs (these individuals would not receive a specific pain test on the lower limb — confirm with trial site)
  • People who are involved in workers' compensation claims, lawsuits, out-of-court settlements, or are receiving financial compensation related to their sickle cell disease
  • People who are already taking part in another clinical trial focused on similar treatment goals
  • People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 317-278-5045

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
25 August 2025
Est. completion
31 August 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Functional brain connectivity characteristics; Somatosensory function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov